Skip to main content

Thomas James E's Form 4 filing

Clarus Therapeutics Inc · filed Apr 21, 2022

Accession no.
0001062993-22-010622
Filed
Apr 21, 2022, 7:04 PM ET
Trade date
Apr 20, 2022
Filing delay
1 day
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 6 non-derivative transactions. Open-market sales total $9.49M. It was filed 1 day after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Thomas James ECIK 000120478910% Owner
TMP Associates LPCIK 000122628010% Owner
Thomas McNerney & Partners LPCIK 000123129110% Owner
Thomas, McNerney & Partners, LLCCIK 000133519610% Owner
TMP Nominee, LLCCIK 000133520010% Owner
Thomas, McNerney & Partners II L.P.CIK 000136957410% Owner
TMP Associates II LPCIK 000138303510% Owner
TMP Nominee II, LLCCIK 000143605410% Owner
Thomas, McNerney & Partners II, LLCCIK 000150593010% Owner

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Apr 20, 2022Common StockSSaleDisposed−1,663,126$2.53F1−$4,207,708.78773,599Indirect
Apr 20, 2022Common StockSSaleDisposed−2,061,685$2.53F1−$5,216,063.05958,989Indirect
Apr 20, 2022Common StockSSaleDisposed−5,722$2.53F1−$14,476.662,661Indirect
Apr 20, 2022Common StockSSaleDisposed−13,630$2.53F1−$34,483.96,340Indirect
Apr 20, 2022Common StockSSaleDisposed−1,164$2.53F1−$2,944.92542Indirect
Apr 20, 2022Common StockSSaleDisposed−7,585$2.53F1−$19,190.053,528Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

The prices reported in this column are weighted average prices at a range of prices between $2.20 and $3.03. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges of the prices reported.

Referenced by the price of 6 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)